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Abstract
5-Fluorouracil (5-FU) is the most frequently used 
chemotherapy agent concomitant with radiotherapy 
in the management of patients with rectal cancer. 
Capecitabine is an oral fluoropyrimidine that mimics the 
pharmaconkinetics of infusional 5-FU. This new drug 
is replacing 5-FU as a part of the combined-modality 
treatment of a number of gastrointestinal cancers. 
While cardiac events associated with the use of 5-FU 
are a well known side effect, capecitabine-induced 
cardiotoxicity has been only rarely reported. Here, we 
reviewed the case of a patient with rectal cancer who 
had a capecitabine-induced coronary vasospasm. The 
most prominent mutation of the dihydropyrimidine 
dehydrogenase  gene was also analyzed.
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INTRODUCTION
5-Fluorouracil (5-FU) is an antimetabolite that is widely 
used in the treatment of  solid tumors. The metabolism 
and pharmacokinetics of  5-FU play important roles 
in determining its efficacy and toxicity. Cardiac events 
related to 5-FU have been described since 1975[1]. Recent 
prospective clinical trials have demonstrated that 2% 
to 10% of  the patients exposed to 5-FU developed 
cardiovascular complications[2,3]. Capecitabine is a 
fluoropyrimidine carbamate active in several solid tumors. 
Its use will be probably increased in the coming years in 
patients with colorectal cancer due to the recent findings 
of  a randomized trial[4]. This clinical trial demonstrated 
that capecitabine is an effective alternative to intravenous 
f luorouracil (5-FU) plus leucovorin in the adjuvant 
treatment of  colon cancer. Capecitabne is converted to 
the active 5-FU by the action of  a series of  enzymes. 
One of  these enzymes, thymidine phosphorylase (TP), 
has higher concentrations in tumor tissue than in 
normal tissue[5]. This suggests that the activation occurs 
preferentially in tumor tissue, providing a favorable ratio 
for toxicity and radiosensitization. Only a few cases of  
capecitabine-induced cardiotoxicity have been reported 
to date[6-10]. The first case described occurred in a patient 
with a prior history of  5-FU-related cardiotoxicity[7]. 
Another report described a case of  coronary spasm after 
drug administration in a woman with moderate arterial 
hypertension[9]. To our knowledge, capecitabine-induced 
coronary vasospasm has been only once reported in 
patients without previous history of  cardiologic events[8]. 
A common etiology for capecitabine and 5-FU-induced 
coronary vasospasm has recently been suggested in a colon 
cancer patient[6].
Walko et al recently compiled a review of  the literature 
reporting adverse effects observed in capecitabine-treated 
patients[10]. Chest pain occurred in 6% of  758 breast 
and colorectal cancer patients treated with capecitabine 
at a dose of  2500 mg/m2 per day in 2 divided doses for 
14 d followed by 1 wk rest. They concluded that this 
complication is more frequent in patients who have a 
history of  coronary artery disease and recommended close 
monitoring for cardiac abnormalities during therapy.
The present case report describes several episodes 
of  angina after oral administration of  capecitabine in a 
patient without prior cardiac history and without previous 
treatment with fluoropyrimidines.
CASE REPORT
A 71 year-old male patient with a moderately differentiated 
adenocarcinoma of  the rectum (uT3N0) was to be treated 
with intensity modulated radiation therapy (48, 34 Gy to 
the 95% of  the Gross Tumor Volume) with Oxaliplatin 
60 mg/m2 on d 1, 8 and 15 and Capecitabine 825 mg/m2 
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bid given on the radiation days. Surgery was to follow 4-6 
wk later.
On March 16, 2005, the patient started radiotherapy; 
he received the first cycle of  Oxaliplatin and was placed 
on Capecitabine. On radiation d 8, he received the 
second chemotherapy cycle without any complications. 
On d 9, he complained of  stomach pain and nausea, and 
gastric protection and antiemetics were increased. On 
d 15, the third cycle of  Oxaliplatin was given, and the 
patient continued with oral capecitabine.  He continued 
to complain of  the same stomach pain which improved 
with vomiting. On d 17 he came to the emergency room 
complaining of  thoracic pressure, sweat, and dyspnea 
during exercise on two different occasions. He had had two 
previous episodes of  chest pain at rest, and one of  these 
episodes woke him up. A cardiac check-up was undertaken. 
The electrocardiogram showed no abnormalities. The 
echocardiogram  demonstrated a normal systolic function 
with an ejection fraction of  0.55. During the stress 
echocardiography with exercise the patient had oppressive 
thoracic pain, ST segment elevation in precordial and 
inferior electrocardiographic leads (Figure 1) and 
contractility changes (akinesia and severe hypokinesia) in 
the territory of  the right and anterior descending coronary 
arteries respectively. Cardiac catheterization did not reveal 
significant coronary artery disease and intracoronary 
injection of  ergonovine failed to induce coronary spasm 
in the epicardial arteries. Capecitabine administration 
was discontinued, and the patient completed the planned 
irradiation course uneventfully. 
Dihydropyrimidine dehydrogenase (DPD) defficiency, 
which may cause accumulation of  potentially cardiotoxic 
5-FU metabolites, was ruled out. DNA was isolated from 
purified lymphocytes by standard procedures and PCR 
amplification of  exon 14 and its flanking intronic regions 
was performed. Further sequence analysis was carried 
out on an Applied Biosystems model 377 automated 
DNA sequencer using the dye-terminator method. DNA 
sequence was clearly wild-type (Figure 2).
DISCUSSION
Capecitabine is converted to 5´-deoxy-5-fluorocytudine 
(5'DFCR) by carboxylesterase in the liver, then to 5´DFUR 
by cytidine deaminase, and finally to 5-FU in tumor tissue 
by pyrimidine nucleoside phosphorylase. TP, an angiogenic 
substance identical to the angiogenic agent “platelet 
derived endothelial cell growth factor” (PD-ECGF)[11,12], 
is required  for the final activation step of  the prodrug. 
TP has been found to be expressed in atherosclerotic 
plaques[13]. This fact could explain the higher risk in 
patients with a prior history of  coronary disease. 
Deficiency of  dihydropyrimidine dehydrogenase 
(DPD), the rate-limiting enzyme in fluoropyrimidines 
catabolism, has been linked to toxic side effects of  these 
drugs. The most prominent mutation of  the DPD gene 
resulting in severe DPD deficiency is a G to A mutation 
in the GT 5’-splice recognition site of  intron 14 (exon 
14-skipping mutation). The corresponding mRNA lacks 
exon 14, and the enzymatic activity of  the translated DPD 
protein is virtually absent (Figure 2). 
Myocardial injury, thrombogenic effects, immunoallergic 
reaction, and ischemia secondary to coronary artery 
spasm have all been implicated in the mechanism of  
5-FU-induced cardiac toxicity, although coronary spasm 
is thought to be the main one[14-17]. Capecitabine toxicity 
is thought to have the same etiology as 5-FU, although 
Capecitabine and its metabolites are minimally cytotoxic in 
vitro compared with 5-FU[18]. 
Coronary spasm is defined as an abnormal contraction 
of  an epicardial coronary artery resulting in myocardial 
ischemia. The commonly associated manifestations of  
myocardial ischemia are oppressive chest pain and ST-
segment alterations on the electrocardiogram[19]. However, 
the most sensitive marker of  myocardial ischemia is the 
appearance of  a wall motion abnormality, which can be 
detected by echocardiography[20].
Our patient presented with rest and exercise-induced 
angina, and the stress echocardiogram revealed exercise-
induced cardiac ischemia in the territory of  the right 
and anterior descending coronary arteries. The coronary 
angiography was normal, both in baseline conditions and 
during intracoronary ergonovine injection. The absence 
of  epicardial coronary stenosis ruled out atherosclerotic 
coronary disease as the cause of  ischemia. The expected 
finding in this case was ergonovine-induced coronary 
spasm, but it failed to occur. Sometimes the test is negative 
in patients with spontaneous spasm because the sensitivity 
of  ergonovine to induce spasm is below 100%. Another 
explanation for the discrepancy between the exercise stress 
test and the angiographic findings is the occurrence of  
spasm at the microvascular level, in small coronary vessels.
Ⅰ aVR V1 V4 
Ⅱ aVL V2 V5 
Ⅲ aVF V3 V6
Figure 1   EKG during  the stress ecocardiography. ST elevation in anterior (V4-V6) 
and inferior leads (DⅡ, DⅢ, aVF).
          250                                                260
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Figure 2  Wild-type sequence at 5'-splice recognition site of intron 14 in DPD 
gene.
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In conclusion, capecitabine should be considered a 
drug with cardiotoxic potential even in the absence of  
prior cardiac history. It can induce coronary spasm at the 
macro or microvascular level.
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